blenrep - Robuta Search

https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-approved-in-china-for-treatment-of-2lplus-relapsedrefractory-multiple-myeloma/ Blenrep (belantamab mafodotin) approved in China for treatment of 2L+ relapsed/refractory multiple... As the only anti-BCMA approved in 2L+ multiple myeloma in China, Blenrep provides a new and needed mechanism of action in therapy. https://www.gsk.com/en-gb/media/press-releases/blenrep-belantamab-mafodotin-in-combination-receives-breakthrough-therapy-designation-in-china-for-treatment-of-relapsedrefractory-multiple-myeloma/ Blenrep (belantamab mafodotin) in combination receives Breakthrough Therapy Designation in China... Granted based on results from phase III head-to-head DREAMM-7 trial. belantamab mafodotin breakthrough therapy blenrep combination receives https://www.tga.gov.au/resources/auspar/blenrep Blenrep | Therapeutic Goods Administration (TGA) May 4, 2026 - Blenrep approved for the treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received... blenrep therapeutic goods administration tga https://www.businesstimes.com.sg/companies-markets/gsk-stop-selling-blood-cancer-drug-blenrep-united-states GSK to stop selling blood cancer drug Blenrep in United States - The Business Times GSK will stop selling its blood cancer drug Blenrep in the United States, it said on Tuesday (Nov 22), representing the latest in a series of setbacks for the... https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-from-dreamm-7-head-to-head-phase-iii-trial-for-blenrep/ GSK announces positive results from DREAMM-7 head-to-head phase III trial for Blenrep in... Blenrep plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex. https://www.gsk.com/en-gb/media/press-releases/gsk-announces-extension-of-us-food-and-drug-administration-review-period-for-blenrep-belantamab-mafodotin-blmf-in-relapsedrefractory-multiple-myeloma/ GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab... New PDUFA date scheduled for 23 October 2025. food and drug administration https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/ GSK provides update on DREAMM-3 phase III trial for Blenrep in relapsed/refractory multiple myeloma... DREAMM-3 did not meet its primary endpoint of progression-free survival (PFS)